IceCure Medical Ltd (NASDAQ:ICCM) Q4 2022 Earnings Call Transcript

Page 4 of 4

They believe that the results are promising in the interim, and they believe that this is indication that they will be more than happy to use it. And actually, we are treating – we are doing this study for clinical evidence. We have the kidney cancer cryoablation as part of our intended use and indication to use both in Europe and also in other countries. So, they believe that the interim results are showing very promising results.

Chaitanya G.: Thank you so much.

Operator: There are no further questions at this time. This concludes the IceCure fourth quarter and full-year 2022 results conference call. Thank you for your participation. You may go ahead and disconnect.

Follow Icecure Medical Ltd.

Page 4 of 4